Your shopping cart is currently empty

LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) in the brain of free-ranging mice and modulates their emotional behaviour.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock |
| Description | LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) in the brain of free-ranging mice and modulates their emotional behaviour. |
| Targets&IC50 | NAPE-PLD:0.86 μM |
| In vitro | In HEK293T cells transfected with hNAPE-PLD, LEI-401 (0.04 - 20 μM; 30 minutes) dose-dependently reduces the labeling of NAPE-PLD, with an IC50 of 0.86 μM. LEI-401 decreases the levels of NAE in Neuro-2a cells but does not reduce them in NAPE-PLD KO cells[1]. |
| In vivo | The in vivo pharmacokinetic profile of LEI-401 was evaluated in the plasma of C57BL/6J mice following intraperitoneal (i.p., 30 mg/kg), oral (p.o., 10 mg/kg), or intravenous (i.v., 1 mg/kg) administration. The results demonstrate that LEI-401 is an active NAPE-PLD inhibitor in vivo, indicating its suitability for studying the physiological role of NAPE-PLD[1]. |
| Synonyms | LEI 401 |
| Molecular Weight | 421.54 |
| Formula | C24H31N5O2 |
| Cas No. | 2393840-15-6 |
| Smiles | O[C@H]1CCN(C1)c1cc(nc(n1)N1CCC[C@H](C1)c1ccccc1)C(=O)NCC1CC1 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (189.78 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (7.83 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.